AstraZeneca amends collaboration with Ironwood

Writer, Stock Market Wire
Wednesday, September 18, 2019 - 07:16

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals in China mainland, China Hong Kong, and China Macau for Linzess.

This new agreement gives AstraZeneca full responsibility for developing, manufacturing, and commercialising Linzess in China.

Linzess is a first-in-class new treatment for patients with irritable bowel syndrome with constipation (IBS-C).

It is expected to be launched later this year, as Linzess was approved in China by the National Medical Products Administration in January 2019.

AstraZeneca will pay Ironwood three non-contingent payments, totalling $35m, between 2021 and 2024. In addition, Ironwood could receive up to $90m in milestone payments, contingent on the achievement of certain sales targets.


Related content

AstraZeneca diabetes drug approved by European Commission

AstraZeneca said its drug to improve glucose levels in adults with type-2 diabetes had been approved by the European Commission.

The approval was based...

Fri, 15/11/2019 - 07:42


AztraZeneca, MSD neurofibromatosis drug application accepted, granted priority review in US

AstraZeneca and MSD said their application for a drug used to treat paediatric patients suffering from neurofibromatosis had been accepted by the US Food and...

Thu, 14/11/2019 - 07:36


Four stocks priced for perfection and likely to disappoint investors

Author: 

Controversial Brexiteer hedge fund manager Crispin Odey is fond of saying that cycles never die, or what goes up inevitably comes back down. What this...

Thu, 14/11/2019 - 00:00


AstraZeneca announces positive results for lupus drug from clinical trial

AstraZeneca said its lupus drug had shown superior results compared with a placebo in a clinical trial.

On the primary endpoint, lupus drug, anifrolumab, achieved...

Tue, 12/11/2019 - 07:35


AstraZeneca's drug to treat anaemia in kidney disease patients meets primary goal

AstraZeneca said pooled analyses had shown that its drug used to treat patients with anaemia from chronic kidney disease had met its primary goal with...

Mon, 11/11/2019 - 07:30